EGFR and non-small cell lung carcinoma: showed that the good response of patients with rare EGFR mutations in NSCLC, including patients with exon 20 insertion or G719X, L861Q, or S768I mutations (69), was associated with the concomitant expression of PD-L1 in the TME (70) and the high incidence of CD8+ tumor-infiltrating lymphocytes (TILs).